Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Chien-Chun Steven Pai, … , Gillian Kingsbury, Lawrence Fong
Chien-Chun Steven Pai, … , Gillian Kingsbury, Lawrence Fong
Published December 10, 2018
Citation Information: J Clin Invest. 2019;129(1):349-363. https://doi.org/10.1172/JCI123391.
View: Text | PDF
Research Article Immunology Oncology Article has an altmetric score of 25

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity

  • Text
  • PDF
Abstract

While immune checkpoint blockade leads to potent antitumor efficacy, it also leads to immune-related adverse events in cancer patients. These toxicities stem from systemic immune activation resulting in inflammation of multiple organs, including the gastrointestinal tract, lung, and endocrine organs. We developed a dual variable domain immunoglobulin of anti-CTLA4 antibody (anti-CTLA4 DVD, where CTLA4 is defined as cytotoxic T lymphocyte–associated antigen-4) possessing an outer tumor-specific antigen-binding site engineered to shield the inner anti-CTLA4–binding domain. Upon reaching the tumor, the outer domain was cleaved by membrane type-serine protease 1 (MT-SP1) present in the tumor microenvironment, leading to enhanced localization of CTLA4 blockade. Anti-CTLA4 DVD markedly reduced multiorgan immune toxicity by preserving tissue-resident Tregs in Rag 1–/– mice that received naive donor CD4+ T cells from WT C57BL/6j mice. Moreover, anti-CTLA4 DVD induced potent antitumor effects by decreasing tumor-infiltrating Tregs and increasing the infiltration of antigen-specific CD8+ T lymphocytes in TRAMP-C2–bearing C57BL/6j mice. Treg depletion was mediated through the antibody-dependent cellular cytotoxicity (ADCC) mechanism, as anti-CTLA4 without the FcγR-binding portion (anti-CTLA4 DANA) spared Tregs, preventing treatment-induced toxicities. In summary, our results demonstrate an approach to anti-CTLA4 blockade that depletes tumor-infiltrating, but not tissue-resident, Tregs, preserving antitumor effects while minimizing toxicity. Thus, our tumor-conditional anti-CTLA4 DVD provides an avenue for uncoupling antitumor efficacy from immunotherapy-induced toxicities.

Authors

Chien-Chun Steven Pai, Donald M. Simons, Xiaoqing Lu, Michael Evans, Junnian Wei, Yung-hua Wang, Mingyi Chen, John Huang, Chanhyuk Park, Anthony Chang, Jiaxi Wang, Susan Westmoreland, Christine Beam, Dave Banach, Diana Bowley, Feng Dong, Jane Seagal, Wendy Ritacco, Paul L. Richardson, Soumya Mitra, Grace Lynch, Pete Bousquet, John Mankovich, Gillian Kingsbury, Lawrence Fong

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2009 Total
Citations: 2 9 11 25 11 13 4 1 1 77
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2021 (11)

Title and authors Publication Year
Targeting the spectrum of immune checkpoints in prostate cancer
LA Sena, SR Denmeade, ES Antonarakis
Expert Review of Clinical Pharmacology 2021
Generation of vascular chimerism within donor organs
S Cohen, S Partouche, M Gurevich, V Tennak, V Mezhybovsky, D Azarov, S Soffer-Hirschberg, B Hovav, H Niv-Drori, C Weiss, A Borovich, G Cohen, A Wertheimer, G Shukrun, M Israeli, V Yahalom, D Leshem-Lev, L Perl, R Kornowski, A Wiznitzer, A Tobar, M Feinmesser, E Mor, E Atar, E Nesher
Scientific Reports 2021
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
N Sobhani, DR Tardiel-Cyril, A Davtyan, D Generali, R Roudi, Y Li
Cancers 2021
In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET
N Zhao, C Bardine, AL Lourenço, Y Wang, Y Huang, SJ Cleary, DM Wilson, DY Oh, L Fong, MR Looney, MJ Evans, CS Craik
ACS Central Science 2021
Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
J Guo, Y Liang, D Xue, J Shen, Y Cai, J Zhu, YX Fu, H Peng
Cell Research 2021
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
X Cai, H Zhan, Y Ye, J Yang, M Zhang, J Li, Y Zhuang
Frontiers in Genetics 2021
Immune-Related Genes to Construct a Novel Prognostic Model of Breast Cancer: A Chemosensitivity-Based Study
ZM Deng, W Hu, FF Dai, MQ Yuan, M Hu, YX Cheng
Frontiers in immunology 2021
Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies
J Cao, M Zhang, B Wang, L Zhang, F Zhou, M Fang
Frontiers in Oncology 2021
Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
X Cao, Y Liang, Z Hu, H Li, J Yang, EJ Hsu, J Zhu, J Zhou, YX Fu
Nature Communications 2021
Switchable immune modulator for tumor-specific activation of anticancer immunity
Y Zhao, YQ Xie, SV Herck, S Nassiri, M Gao, Y Guo, L Tang
Science Advances 2021
Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response
L Jacobs, L Yshii, S Junius, N Geukens, A Liston, K Hollevoet, P Declerck
Cancer Gene Therapy 2021

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 21 X users
Referenced in 2 patents
On 3 Facebook pages
110 readers on Mendeley
See more details